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Abstract
Background: Chronic myeloid leukaemia (CML) is a haematopoietic stem cell disorder, almost
always characterized by the presence of the Philadelphia chromosome (Ph), usually due to
t(9;22)(q34;q11) or its variants. The Ph results in the formation of the BCR/ABL1 fusion gene, which
is a constitutively activated tyrosine kinase. Around 1% of CML patients appear to have a Ph
negative karyotype but carry a cryptic BCR/ABL1 fusion that can be located by fluorescence in situ
hybridisation (FISH) at chromosome 22q11, 9q34 or a third chromosome. Here we present FISH
mapping data of BCR and ABL1 flanking regions and associated chromosomal rearrangements in 9
Ph negative BCR/ABL1 positive CML patients plus the cell line CML-T1.
Results: BCR/ABL1 was located at 9q34 in 3 patients, 22q11 in 5 patients and CML-T1 and 22p11
in 1 patient. In 3 of 6 cases with the fusion at 22q11 a distal breakpoint cluster was found within a
280 Kb region containing the RAPGEF1 gene, while in another patient and the CML-T1 the distal
breakpoint fell within a single BAC clone containing the 3' RXRA gene. Two cases had a duplication
of the masked Ph while genomic deletions of the flanking regions were identified in 3 cases. Even
more complex rearrangements were found in 3 further cases.
Conclusion: BCR/ABL1 formation resulted from a direct insertion (one step mechanism) in 6
patients and CML-T1, while in 3 patients the fusion gene originated from a sequence of
rearrangements (multiple steps). The presence of different rearrangements of both 9q34 and 22q11
regions highlights the genetic heterogeneity of this subgroup of CML. Future studies should be
performed to confirm the presence of true breakpoint hot spots and assess their implications in Ph
negative BCR/ABL1 positive CML.
Background
Chronic myeloid leukaemia (CML) is a pluripotent hae-
matopoietic stem cell disorder defined by expression of
the BCR/ABL1 fusion gene, a constitutively activated tyro-
sine kinase, harbored by the Philadelphia chromosome
(Ph), which is a result of a t(9;22)(q34;q11) or a related
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variant translocation [1]. In ~1% of the CML patients the
bone marrow cells appear to be Ph negative by G-band-
ing, although the BCR/ABL1 fusion gene can be identified
by molecular means and located by fluorescence in situ
hybridisation (FISH) on chromosome 22q11, 9q34 or
even a third chromosome. The biology and clinical signif-
icance of the genetic rearrangements in Ph negative BCR/
ABL1 positive disease have been widely discussed follow-
ing the first descriptions [2-5]. Two mechanisms for the
formation of the chimeric gene in masked Ph positive
cells have been postulated: either by insertion of ABL1
into the BCR region (or vice versa) or by a multiple step
model where a classical t(9;22) is followed by a transloca-
tion of both products and/or another autosome, thereby
restoring the normal chromosome morphology. In both
instances, more than the 2 breaks associated with classical
t(9;22) are implicated. Although as early as 1990 Morris
et al. [6] provided evidence that the insertion involves
additional sequences distal to the 3' ABL1 site, the extent
of the genomic rearrangements in this form of CML are
unknown.
In view of the few studies published with a precise map of
the insertions [7-10], we aimed to construct an accurate
map of the insertions in the cell line CML-T1 [11] and 9
patients with Ph negative BCR/ABL1 positive CML using a
range of FISH probes obtained from BAC clones. The
fusion gene was identified at 9q34 (3 patients), 22q11 (5
patients and CML-T1) and 22p11 (3 patients), resulting in
relocation of sequences well in excess of either 3' ABL or
5' BCR  by means of a direct insertion (6 patients and
CML-T1) or a sequence of events (3 patients). Recurrent
distal breakpoints were found at the regions of RAPGEF1
and RXRA genes.
Methods
Nine archival bone marrow chromosome preparation
samples of CML patients (7 females and 2 males) with Ph
negative BCR/ABL1 positive disease collected from Ham-
mersmith and Royal Free Hospitals (London, UK),
together with the cell line CML-T1, were investigated
(Table 1). All samples tested positive for BCR/ABL1 fusion
by PCR. Investigations were carried out on bone marrow
samples obtained at presentation. G-banding and molec-
ular cytogenetic analysis, including chromosome painting
and FISH mapping with locus specific probes, were per-
formed following protocols in routine use [12]. A mini-
mum of 25 metaphase and over 100 interphase cells after
short term in vitro culturing were analysed and results
described following ISCN (2005). Five of the samples in
this cohort (cases 1–3, 7 & 8) were part of another study
[13].
In all samples, FISH with the commercially available LSI
BCR/ABL1 Dual Color, Dual Fusion Translocation Probe
("D-FISH", Vysis, Downers Grove, IL, USA) was initially
performed using manufacturer's protocol to identify the
chromosome location of the BCR/ABL1 fusion gene. FISH
mapping was carried out with Bacterial Artificial Chromo-
somes (BAC) clones obtained from the BACPAC
Resources Center (Children's Hospital Oakland Research
Institute, Oakland, CA, USA), the Sanger Centre (Cam-
bridge, UK) and Invitrogen (Paisley, UK) (Table 2).
Clones were grown in Luria-Bertani medium with Chlo-
ramphenicol (20 μg/ml), BAC DNA extracted with a QIA-
GEN Large-Construct Kit (Qiagen, West Sussex, UK) and
directly labelled with either Spectrum Orange or Spectrum
Green dUTPs with a Nick Translation Kit (Vysis). BAC
DNA from chromosomes 9 and 22 belonging to the
Human 32 K Clone Set from the BACPAC Resources
Center was amplified with a GenomePlex Single Cell
Whole Genome Amplification Kit (Sigma-Aldrich, Dorset,
UK) and labelled as described before.
BAC RP11-164N13 was used to target BCR gene. Since this
BAC covers both major and minor BCR breakpoints, it is
found split when BCR gene is rearranged. RP11-61N10
covers  BCR  non-coding sequences centromeric to the
Table 1: Characteristics of the samples.
Case no. Sample type Karyotype BCR/ABL1 fusion
1 Bone marrow 46, XX [20] e13a2
2 Bone marrow 46, XX [20] e14a2
3 Bone marrow 46, XX [20] e13a2
4 Bone marrow 46, XX [20] NA
5 Cell line (CML-T1) 92 < 4n > XXX, t(6;7)(q24;q35)x2, del(11)
(q?22.3)x2[12]/46, XX, idem[18]
e13a2
6 Bone marrow 46, XX [20] e13a2
7 Bone marrow 46, XX [20] e13a2/e14a2
8 Bone marrow 46, XX [20] e13a2
9 Bone marrow 46, XX [20] NA
10 Bone marrow 46, XX [20] NA
NA: Not availableMolecular Cytogenetics 2008, 1:14 http://www.molecularcytogenetics.org/content/1/1/14
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breakpoint and it was used to identify 5' BCR  region.
RP11-83J21, which covers the 3' end of ABL1 incorporat-
ing the whole of the coding region, was used to identify
the sequences telomeric of the ABL1 breakpoint, whereas
RP11-57C19 was used to identify the ABL1 sequences cen-
tromeric of the breakpoint.
The BAC clones and genes were located according to the
UCSC database, hg17 (University of California Santa
Cruz, CA, USA) [14]. Mapping data for the 32 K human
clone set was obtained from the BACPAC Resources
Center website [15] and used to assess the size of the
sequences found to be rearranged. In addition, sub-telom-
eric probes directly labelled from the regions of 9q, 22q
and 16q were used (Stretton Scientific Ltd, Stretton, UK).
All tests were carried out as dual colour, dual probe FISH.
Digital imaging and karyotyping were carried out using a
SmartCapture and SmartType FISH workstation (Digital
Scientific Ltd, Cambridge, UK).
Array CGH analysis (aCGH) was carried out on the cell
line CML-T1. The aCGH was performed using two plat-
forms – 1 Mb BAC clone chip (SGI2600) [16] and oligo-
nucleotide (105 K Agilent) [17] following manifacturer's
protocol, while data processing and presentations were
carried out using 'in house' software as reported [18,19].
Results
A summary of the molecular cytogenetic investigations
carried out on BCR/ABL1 positive samples from 9 CML
patients with normal bone marrow (BM) karyotype as
well as the cell line CML-T1 with masked Ph chromosome
is presented Figure 1.
FISH analysis using commercial BCR/ABL1 D-FISH probe 
(Vysis)
The BCR/ABL1 D-FISH probe (Vysis) contains sequences
covering both genes labelled in different colours, so that
rearrangements affecting them can be visualised at chro-
mosome level. The ABL1 probe (red) targets a 650 Kb
region of 9q34.1 including the whole of the ABL1 gene
(173.8 Kb), thus spanning the common breakpoint, and
extends 5' of ABL1 to incorporate the ASS gene. The BCR
probe (green) is represented by two 600 Kb regions of
22q11.2 separated by a 300 Kb gap, one of the regions
covering the entire BCR gene and extending 5' of it in
order to include the IGLV gene, and the other starting 300
Kb telomeric of BCR and ending at 900 Kb 3' of the gene.
Table 2: Summary of the BAC clones used for FISH analysis, their genomic address and source.
BAC Clone Chromosome
 address
Start End Source
RP11-17O4 9q34.1 129,342,001 129,449,609 Sanger
RP11-138E2 9q34.1 129,759,745 129,938,526 Sanger
RP11-88G17 9q34.1 129,970,404 130,152,614 Sanger
RP11-57C19 9q34.1 130,510,099 130,683,561 Invitrogen
RP11-83J21 9q34.1 130,681,562 130,858,027 BACPAC
RP11-544A12 9q34.1 130,994,805 131,191,826 Invitrogen
RP11-643E14 9q34.1 131,186,189 131,363,951 Sanger
CTD-2107G12 9q34.1 131,334,305 131,468,329 BACPAC (32K Clone Set)
RP11-40A7 9q34.1 131,422,266 131,599,379 BACPAC
RP11-323H21 9q34.1 131,659,962 131,844,139 BACPAC
CTD-2505O5 9q34.1 131,842,073 131,989,317 BACPAC (32K Clone Set)
RP11-666F23 9q34.1 132,014,407 132,158,747 BACPAC (32K Clone Set)
RP11-81P5 9q34.1 132,115,450 132,308,214 BACPAC
RP11-326L24 9q34.1-q34.2 132,884,992 133,078,984 Sanger
RP11-153P4 9q34.2 133,571,299 133,750,426 Sanger
RP11-145E17 9q34.2 134,270,752 134,427,189 Sanger
RP11-92B21 9q34.2 134,517,511 134,693,859 Sanger
RP11-751H16 9q34.3 134,857,931 135,039,874 BACPAC (32K Clone Set)
RP11-413M3 9q34.3 136,526,666 136,715,127 Sanger
RP11-424E7 9q34.3 138,161,638 138,393,244 BACPAC (32 K Clone Set)
RP11-61N10 22q11.2 21,728,291 21,917,898 BACPAC
RP11-164N13 22q11.2 21,892,457 22,086,126 BACPAC
RP11-529P21 22q11.2 22,073,257 22,227,046 BACPAC (32 K Clone Set)
RP11-223O10 22q11.2 22,203,038 22,369,574 BACPAC (32 K Clone Set)
RP11-698L6 22q11.2 22,333,501 22,518,106 BACPAC (32 K Clone Set)
RP11-594L10 22q11.2 22,725,284 22,866,905 BACPAC (32 K Clone Set)
RP11-446O3 22q11.2 22,846,809 23,014,392 BACPAC (32 K Clone Set)
RP11-765G14 22q11.2 23,590,296 23,758,574 InvitrogenMolecular Cytogenetics 2008, 1:14 http://www.molecularcytogenetics.org/content/1/1/14
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The application of this probe revealed the BCR/ABL1
fusion at three different chromosome sites: at 22q11.2
(samples no 1–6), at 22p11 (sample no 7) and at 9q34
(samples no 8–10). There was evidence for the formation
of the reciprocal ABL1/BCR fusion in just one patient (no
4), which showed 2 fusion signals at der(22) and der(9).
In the remaining cases only 1 fusion signal was observed,
irrespective of the fusion gene location.
In addition, D-FISH also revealed the presence of different
clones with further rearrangements in CML-T1 and
patients no 1 and 3. CML-T1 was found to harbour 3
clones: i) 7 out of 20 metaphases (35%) showed a 2 red 2
fusion signal pattern typical of diploid cells with duplica-
tion of the masked Ph and no normal 22 homologue (loss
of the green signal); ii) 7 out of 20 metaphases (35%)
showed a 4 red 4 fusion pattern for tetraploid cells with
duplication of the masked Ph and no normal 22; iii) 6 out
of 20 metaphases (30%) showed a 2 red 4 fusion pattern
for tetraploid cells with duplication of the masked Ph, no
normal 22 and deletion of 5' ABL1 (loss of two red sig-
nal). Patient no 3 had also developed a sub-clone with a
duplication of the masked Ph and loss of the normal 22
homologue (2 red 2 fusion D-FISH pattern), as seen in 4
out of 20 metaphases (20%). On the other hand, D-FISH
in patient no 1 showed a 1 red 1 green 1 fusion signal pat-
tern, uncovering a deletion of sequences centromeric to
ABL1 at the der(9)ins(22;9) in all cells screened (loss of 1
red signal).
Patients with BCR/ABL1 fusion residing on chromosome 
22q11.2
The BAC clone RP11-83J21 covering 3' ABL1 moved to
22q11 in 6 cases (no 1–6), whereas RP11-57C19
remained at der(9) in all but one (no 1, Figure 1). In
patient no 1, we identified a cryptic genome loss at der(9)
of at least 1.34 Mb in all cells. The sequences deleted, cen-
tromeric of ABL1 breakpoint, were covered by the BAC
Summary of the FISH mapping carried out on Ph negative BCR/ABL1 positive bone marrow cells from 9 CML patients and the  cell line CML-T1 Figure 1
Summary of the FISH mapping carried out on Ph negative BCR/ABL1 positive bone marrow cells from 9 CML 
patients and the cell line CML-T1. Header row shows the location of BCR/ABL1 fusion: 22q11.2 (cases no 1–6), 22p (case 
7) and 9q34.1 (cases 8–10). (a) Map of the 9q34.1-qter region with coloured squares (key on the right) indicating the location 
or deletion of the BAC clones used for FISH analysis (approximate genomic distances to the breakpoint and names of the BAC 
clones on the left). A thick black horizontal line presents the ABL1 breakpoint, which is encompassed by the clones RP11-
57C19 and RP11-83J21. When a breakpoint falls within a BAC, the probe gives a split signal in two different locations. (b) Map 
of the 22q11.2 region with coloured squares (key below) indicating the location or deletion of the BAC clones tested (genomic 
distances and names of the clones on the left). A thick black horizontal line presents the BCR breakpoint, which falls within the 
BAC clone RP11-164N13.Molecular Cytogenetics 2008, 1:14 http://www.molecularcytogenetics.org/content/1/1/14
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clones RP11-57C19 to RP11-17O4. However, it was not
possible to assess the full extend of the deletion due to
lack of material.
In all 6 cases the inserted 9q34 sequences exceeded the 3'
boundaries of the ABL1 gene and estimated to be 720 Kb
long in 1 case (no 1), 1 Mb in 2 cases (no 2–3), between
1.6 Mb and 2.2 Mb in 1 case (no 6) and 3.9 Mb in 2 cases
(no 4–5). The estimated sizes of the insertions were calcu-
lated based on the information of the BAC clones chro-
mosome location available at the UCSC database
(genome build 35). In cases no 1–5 the insertions were
found to stretch distally falling into two sub-groups: a
"small" insertion (720 Kb–1 Mb) and a "large" insertion
(3.9 Mb) (Figure 2). The distal boundary of the "small"
insertion seen in 3 patients (no 1–3) fell within a region
covered by 3 overlapping BAC clones (CTD-2107G12,
RP11-40A7 and RP11-323H21), thus forming a break-
point cluster (Figure 2) which was estimated to be 280 Kb
long and found to house several genes: POMT1, UCK1
and RAPGEF1. In further two samples (patient no 4 and
CML-T1) the inserted material was found to be larger
(estimated size of 3.9 Mb) and the distal breakpoint fell
within a single BAC clone (RP11-92B21) containing the 3'
end of the RXRA gene (Figure 2).
High-resolution aCGH analysis of the cell line CML-T1
identified a gain at 9q34.1 starting at ABL1 breakpoint at
130.6 and covering 3.9Mb in 3' direction until the distal
part of the RXRA gene at 134.5, confirming the FISH map-
ping data (Figure 3). This gain resulted from the duplica-
tion of the der(22)ins(22;9) seen in all CML-T1 cells,
which was always accompanied by loss of the normal 22
homologue. Furthermore, use of D-FISH with CML-T1
BCR/ABL1 fusion at 22q11.2: "small" and "large" insertions with recurrent distal breakpoints Figure 2
BCR/ABL1 fusion at 22q11.2: "small" and "large" insertions with recurrent distal breakpoints. (a) Diagram showing 
the small size ins(22;9)(q11;q34.1q34.1) seen in 3 patients (no 1–3). The BAC clones covering the distal breakpoint region are 
presented with green lines. The ABL1 breakpoint marks the proximal boundary of the insertion (< 1 Mb) while the distal break-
point (shown by red arrows) falls within a 280 Kb breakpoint cluster housing the UCK1, POMT1 and RAPGEF1 genes. (a1) A rep-
resentative metaphase cell in patient no 3 with co-hybridization of FISH probes RP11-323H21 and RP11-413M3, showing a split 
signal from RP11-323H21 (green signals at both chromosome 9 homologues and masked Ph) and duplication of the masked Ph 
(green signals on 2 masked Ph). (a2) BCR/ABL1 D-FISH (Vysis) in patient no 2, showing the absence of green signal at der(9). (b) 
Diagram showing the large size ins(22;9)(q11.2;q34.1q34.2) seen in patient no 4 and CML-T1. The ABL1 breakpoint marks the 
proximal boundary of the 3.9 Mb insertion, while the distal breakpoint lies within the clone RP11-92B21 (red arrow). (b1) A 
representative metaphase cell in patient no 4 with co-hybridization of FISH probes RP11-92B21 and RP11-413M3, showing a 
split signal from RP11-92B21 (green signal at both chromosome 9 homologues and masked Ph). (b2) BCR/ABL1 D-FISH (Vysis) 
in CML-T1, showing absence of green signal at der(9) and duplication of the masked Ph (two fusion signals).Molecular Cytogenetics 2008, 1:14 http://www.molecularcytogenetics.org/content/1/1/14
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Gains and deletions in the Ph negative BCR/ABL1 positive cell line CML-T1 Figure 3
Gains and deletions in the Ph negative BCR/ABL1 positive cell line CML-T1. (a) Array CGH reveals gains of 
sequences downstream of the ABL1 breakpoint. The genome profile of the 9q34.1-qter region is shown at the top and the 
22q11.2-2 region is presented at the bottom, aligned at the ABL1 and BCR breakpoints (vertical dashed line). Results of the 
SGI2600 BAC chip are shown in red and 44 K Agilent oligonucleotide in blue. Both BAC and oligo array detect a gain of the 
9q34 sequences proximally flanked by the ABL1 breakpoint and distally by the RXRA gene. (b) A representative tetraploid met-
aphase cell with co-hybridization of FISH probes RP11-138E2 and RP11-17O4, showing the proximal breakpoint of the 9q34 
deletion arisen in this sub-clone (the arrows show the two missing green signals from RP11-138E2). (c) A representative tetra-
ploid metaphase cell with co-hybridization of RP11-323H21 and a 9q sub-telomeric probe (Stretton), showing the duplication 
of the masked Ph and that the genomic loss affects not the der(9) but the "normal" homologue (the 2 green and 2 red signals 
from the two normal 9 are missing). The top box on the right shows 4 green, 2 red signals as seen in interphase tetraploid cells 
with deletion, while the bottom box on the right shows 6 green, 4 red signals as seen in the interphase tetraploid cells without 
deletion.Molecular Cytogenetics 2008, 1:14 http://www.molecularcytogenetics.org/content/1/1/14
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had previously revealed a deletion of 5' ABL1 in a tetra-
ploid sub-clone. We mapped the length of the deletion,
which was found to be 8.7 Mb long (from RP11-138E2 to
9q telomere) and affect not the der(9)ins(22;9) but the
"normal" 9. This was demonstrated by FISH when co-
hybridizing a BAC clone found within the insert (in
green) and a BAC from chromosome 9 centromeric or tel-
omeric to the inserted sequences (in red). Tetraploid cells
with a deletion displayed 2 red signals from two chromo-
some 9 and 4 green signals from the 4 masked Ph chro-
mosomes. Therefore not only two red signals were
deleted, but also the 2 green signals from the "normal" 9
were missing, demonstrating that the loss had occurred at
the "normal" homologues.
Regarding BCR flanking regions, all probes tested from
chromosome 22 remained at their original locations in
cases no 1, 2, 3 and 5. However, in case no 4, sequences
distal to the BCR  breakpoint and housed by the BAC
clones RP11-164N13, RP11-529P21, RP11-223O10 and
RP11-698L6 were found embedded within the der(9)
chromosome at the 9q34 region (Figure 4). Both RP11-
164N13 and RP11-529P21 gave a split signal pattern
being found at the masked Ph and derivative 9, apart from
the normal 22. The distal breakpoint of the 22 sequences
found at der(9) fell between RP11-698L6 and RP11-
594L10.
Even more complex rearrangements involving a third
chromosome were revealed in another patient (no 6) (Fig-
ure 5). FISH painting and FISH mapping identified a three
BCR/ABL1 at 22q11.2 in patient no 4 results from a multiple step mechanism Figure 4
BCR/ABL1 at 22q11.2 in patient no 4 results from a multiple step mechanism. (a) BCR/ABL1 D-FISH probe (Vysis) 
showing 1 red, 1 green, and 2 fusion signals. The presence of both BCR/ABL1 and ABL1/BCR fusion genes is an evidence of an 
initial t(9;22)(q34;q11.2). (b) A representative metaphase cell with co-hybridization of FISH probes RP11-61N10 and RP11-
164N13, showing a split signal from RP11-164N13. Thus, the proximal boundary of the 22q11.2 sequences identified within the 
structure of the der(9) chromosome coincides with the BCR breakpoint. (c) A representative metaphase cell with co-hybridiza-
tion of FISH probes RP11-698L6 and RP11-446O3. RP11-698L6 is identified at der(9) while RP11-446O3 is found at der(22). 
The distal breakpoint of the 22q11.2 fragment lies between these two BAC clones. (d) Schematic representation of the multi-
ple step rearrangement with chromosomes 9 in red and 22 in green. Red arrowheads show the breakpoints. The presence of 
both 9q34 sequences inserted on der(22) and 22q11.2 sequences inserted on der(9) (black arrows) can be explained by two 
consecutive translocations: an initial t(9;22)(q34;q11.2) followed by a second reciprocal translocation between the two prod-
ucts, with breakpoints distal to both BCR/ABL1 and ABL1/BCR fusion genes.Molecular Cytogenetics 2008, 1:14 http://www.molecularcytogenetics.org/content/1/1/14
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way cryptic translocation t(9;22;16)(q34;q11;q?13) and
found the presence of 9q34.1 sequences sandwiched in
the der(22)(22pter-q22.1::9q34.1::16q?13-qter). The dis-
tal breakpoint of the 9q34.1 fragment fell between RP11-
81P5 and RP11-326L24 and the insertion was therefore
estimated to be 1.6 Mb–2.2 Mb long. All sequences from
chromosome 22 distal to the BCR breakpoint were found
at chromosome 16, while sequences proximal to the
breakpoint remained at 22q11.
Patient with the BCR/ABL1 fusion residing at 22p11
The BCR/ABL1 fusion was unexpectedly found at 22p11
in 1 patient (no 7) (Figure 6). FISH with RP11-164N13
showed one signal at the normal chromosome 22 and a
split signal at the 22p11 and 22q11 regions from the other
homologue. RP11-61N10 was found at the normal 22
and only at the 22p11 region of der(22), thus confirming
the location of BCR/ABL1 fusion at the p arm of the deriv-
ative 22. RP11-529P21, RP11-223O10 and 22qter
remained on 22q11, while all probes tested from RP11-
83J21 to 9qter were found at 22p11.
Patients with the BCR/ABL1 fusion residing at 9q34.1
The BCR/ABL1 fusion was located by FISH at band 9q34.1
in 3 patients (no 8–10) and thought to result from a direct
insertion of 22q11.2 sequences. As expected, the telom-
eric breakpoint was found in all cases within the BAC
clone RP11-164N13, which was always seen at both
der(9) and der(22) (Figure 7). RP11-61N10 was always
found at 9q34, however, due to lack of material it was not
BCR/ABL1 resides at 22q11.2 as a result of a cryptic three-way rearrangement between chromosomes 9, 22 and 16 in patient  no 6 Figure 5
BCR/ABL1 resides at 22q11.2 as a result of a cryptic three-way rearrangement between chromosomes 9, 22 
and 16 in patient no 6. (a) BCR/ABL1 D-FISH probe (Vysis) showing 1 fusion signal at der(22), 2 red signals at 9 and der(9), 1 
green signal at 22 and 1 unexpected green signal at der(16). (b) Chromosome painting confirming the presence of a 
t(9;22;16)(q34;q11;q?13) in an apparently normal G banding karyotype. (c) FISH with co-hybridization of RP11-326L24 and 
RP11-643E14 locating RP11-643E14 at the masked Ph while RP11-326L24 is retained at the der(9). (d) A representative met-
aphase cell with co-hybridization of FISH probes RP11-81P5 and RP11-153P4 identifying RP11-81P5 at the masked Ph. The dis-
tal breakpoint of the 9q34 insert is therefore flanked by the BAC clones RP11-81P5 and RP11-326L24. (e) A representative 
metaphase cell with co-hybridization of FISH probes RP11-92B21 and RP11-223O10 showing RP11-223O10 at normal 22 and 
der(16), thus confirming the relocation of sequences distal to BCR breakpoint at chromosome 16. (f) Schematic representation 
of the three-way rearrangement with chromosomes 9 in red, 16 in yellow and 22 in green; note that the der(22) contains 
material from all three parties. The presence of 9q34.1 sequences embedded within the masked Ph suggests that the t(9;22;16) 
could be a result of a two stage event: firstly ins(22;9) followed by translocation between der(22)ins(9;22) and 16q.Molecular Cytogenetics 2008, 1:14 http://www.molecularcytogenetics.org/content/1/1/14
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BCR/ABL1 fusion resides at 22p11 in patient no 7 Figure 6
BCR/ABL1 fusion resides at 22p11 in patient no 7. (a) BCR/ABL1 D-FISH probe (Vysis) showing a split green signal from 
BCR within the masked Ph. There is only 1 fusion signal located at der(22), another green signal at the same (der22), one green 
signal at normal 22 and 2 red signals at both chromosomes 9. (b) A representative metaphase cell with co-hybridization of FISH 
probes RP11-424E7 and RP11-61N10 identifying both probes at the p arm of the masked Ph. (c) A representative metaphase 
cell with co-hybridization of a 9q sub-telomeric probe (Stretton) and RP11-83J21, showing the presence of the two probes at 
22p11 and indicating that all sequences distal to ABL1 breakpoint had moved to 22p11. (d) A representative metaphase cell 
with co-hybridization of a 22q sub-telomeric probe (Stretton) and RP11-83J21, showing that the 22q telomere is retained at its 
original location. (e) Schematic representation of the events that may have lead to the formation of BCR/ABL1 fusion gene and 
its unusual location at 22p11, with chromosome 9 in red and 22 in green. Sequences distal to BCR breakpoint are found at their 
original location while 5' BCR and 9q34 sequences distal to ABL1 breakpoint (including the telomere) are relocated at 22p11. 
This could be explained by an initial t(9;22)(q34;q11) followed by a three-way translocation between 9q34, 22q11 and 22p11, 
which would require 5 breaks (red arrowheads). (f) The unusual location of BCR/ABL1 at 22p11 could also be a result of an 
initial ins(9;22)(q34;q11q11) followed by a translocation between der(9) and the p arm of der(22). This sequence of events 
would need also the same amount of breaks (red arrowheads) and therefore cannot be rule out.Molecular Cytogenetics 2008, 1:14 http://www.molecularcytogenetics.org/content/1/1/14
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possible to assess the proximal breakpoint of the 22q11
insertion. All BACs tested from 9q34 remained at their
respective location on chromosome 9 in all 3 patients.
In patient no 8, the insertion was accompanied in all cells
by loss of a region at least 1.77 Mb long from 22q11.2 and
immediately distal to the BCR breakpoint, covered from
BCR/ABL1 fusion resides at 9q34.1 in 3 patients Figure 7
BCR/ABL1 fusion resides at 9q34.1 in 3 patients. (a) A representative metaphase cell hybridized with a BCR/ABL1 D-FISH 
probe (Vysis) showing the presence of 1 fusion signal at der(9), 1 red signal at 9 and 2 green signals at both chromosomes 22 as 
seen in patients no 9 and 10. (b) A representative metaphase cell with co-hybridization of FISH probes RP11-61N10 and RP11-
164N13 showing 2 fusion signals at 22 and der(9), plus 1 green signal at der(22), as seen in patients no 9 and 10. RP11-164N13 
is therefore split, with the 5' BCR sequences relocated at der(9). (c) BCR/ABL1 D-FISH probe (Vysis) in patient no 8 showing 1 
fusion signal at der(9), 1 red signal at 9 and 1 green signal at 22. The green signal from der(22) is deleted. (d) A representative 
metaphase cell with co-hybridization of FISH probes RP11-61N10 and RP11-594L10 giving a fusion signal at normal 22 and one 
red signal from RP11-61N10 at der(9), confirming that the BCR sequences moved to der(9) are centromeric of the breakpoint. 
There is again one green signal missing, because the deletion at der(22) includes not only 3' BCR but also at least 1.77 Mb distal 
to the breakpoint.Molecular Cytogenetics 2008, 1:14 http://www.molecularcytogenetics.org/content/1/1/14
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the 3' end of RP11-164N13 to at least RP11-765G14 (Fig-
ure 1).
Discussion
Since the first description of a Ph negative BCR/ABL1 pos-
itive CML patient [2], several studies have been published
reporting similar cases. Most of them are focused on the
presence and location of the BCR/ABL1 fusion in CML
patients with masked Ph chromosome and commonly
achieved by application of commercial FISH probes,
which have been proved to be very useful to identify the
presence and location of the BCR/ABL1 fusion gene in
CML patients with no distinguishable Ph chromosome.
These studies have established the importance of FISH
tests for the diagnosis and therapy monitoring of Ph neg-
ative BCR/ABL1 positive CML. However, the commercial
probes don't provide enough information to understand
the mechanisms involved in the formation of the masked
Ph chromosome.
We used FISH mapping with BAC probes in order to study
the formation of the BCR/ABL1 fusion and the underlying
genomic rearrangements in 9 CML patients with Ph nega-
tive BCR/ABL1 positive CML and the cell line CML-T1.
The formation of the fusion gene resulted from the reloca-
tion of not only the 3' ABL1 sequences within the BCR
region at chromosome 22q11.2 or 5' BCR  sequences
within ABL1  region at 9q34.1, but also a considerable
amount of flanking material, leaving the chromosome
morphology apparently intact.
The fusion gene was located at 9q34.1 in 3 patients, at
22q11.2 in 5 patients and CML-T1, and at 22p11 in
another patient. 5 out of the 6 cases with a 9q34 insertion
at 22q11 displayed recurrent distal breakpoints that fell
within two gene bearer regions. Thus, in 3 patients a com-
mon breakpoint cluster of 280 Kb was found. According
to UCSC database, this region houses 3 genes: POMT1
(protein-O-mannosyltransferase1),  UCK1  (uridine-cyti-
dine kinase 1) and RAPGEF1 (guanine nucleotide releas-
ing factor for RAP1; also known as C3G). In another
patient and CML-T1 the breakpoint fell within a single
BAC clone encompassing the 3' end of RXRA gene (retin-
oid × receptor alpha). Although further investigations
were not carried out in this study, both RAPGEF1 and
RXRA belong to pathways the disruption of which may be
relevant to the evolution of the patients. RAPGEF1 has
been shown to have transformation suppressor activity
towards several oncogenes [20,21] and also interact with
BCR/ABL1  [22].  RXRA  belongs to a family of nuclear
receptors that target multiple signalling pathways [23]
and its downregulation has been showed to be critical for
neutrophil granulocytes differentiation [24]. Other stud-
ies found RXRA to contribute in acute promyelocytic leu-
kaemia transformation [25,26]. Although we have no
direct evidence for the immediate involvement of either
RAPGEF1 or RXRA genes, their potential role merits fur-
ther investigation.
Two other mapping studies that found similar insertions
have been published [7,8]. In the first study, the authors
used FISH mapping to identify the rearrangements
involved in 2 Ph negative CML patients with variant trans-
locations. A 3 Mb insertion from 22q11 into ABL1 was
identified in 1 patient, while the other had a 9q34 inser-
tion at the BCR region with a distal breakpoint falling
within the clone RP11-353C22 (genome address:
31,278,002–131,588,248). This result matches with our
findings since the latter BAC is located within the same
280 Kb common breakpoint region identified in 3
patients of our study. On the other hand, Valle et al. [7]
found a 5.6 Mb insertion of 9q34 sequences into BCR.
This insertion is larger than the ones identified in our
study and was not accompanied by any deletions or other
rearrangements.
Deletions of 5' ABL1  and/or 3' BCR  sequences at the
der(9) chromosome in patients with classical and variant
Ph translocations [27] have been shown to have adverse
prognostic value in CML patients treated with interferon
[28], although their impact in patients being treated with
tyrosine kinase inhibitors is controversial [29-31]. Dual
colour, dual fusion translocation FISH probes spanning
the BCR and ABL1 genes are very useful for revealing these
events but they have a limited value in interphase nuclei
in patients with masked Ph, since often the merging of the
5' BCR and 3' ABL1 signals by simple insertion leads to an
apparent loss of one fusion signal that can be falsely
assessed as deletion [13]. Thus, D-FISH (Vysis) in a
patient with a direct ins(22;9) gives a 2 red, 1 green, 1
fusion signal pattern, which is the same pattern obtained
in case of a typical t(9;22) with deletion of 5' ABL1 at
der(9). If the patient has a direct ins(9;22) the D-FISH sig-
nal pattern is 1 red, 2 green, 1 fusion, which could be mis-
taken for a typical t(9;22) with deletion of 3' BCR  at
der(9). Furthermore, Ph negative BCR/ABL1  positive
patients with either a cryptic deletion of 5' ABL1 or 3' BCR
show a 1 red, 1 green, 1 fusion D-FISH pattern, also typi-
cal for a t(9;22) with deletion of the reciprocal ABL1/BCR
fusion. Therefore, when a deletion signal pattern is
detected by interphase FISH with a dual colour, dual
fusion probe, it is essential to look also at the metaphases
in order to be able to differentiate a classical t(9;22) with
deletion from a simple insertion.
Batista et al [32] reported a Ph negative BCR/ABL1 positive
patient with an insertion of ABL1  into BCR  associated
with a deletion of the ASS – 5' ABL1 region. Zagaria et al
[8] also reported two cases of CML patients with masked
Ph and associated deletions: one patient with a crypticMolecular Cytogenetics 2008, 1:14 http://www.molecularcytogenetics.org/content/1/1/14
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ins(9;22) and a deletion of 5' ABL1 and 3' BCR regions;
the other patient with a multi-step variant translocation
and a deletion of around 400 Kb telomeric of the ABL1
gene. In addition to them, De Melo et al [13] identified
with commercial triple-colour FISH probes 5' ABL1 dele-
tions in 2 patients and 3' BCR deletion in 1 patient out of
14 CML patients with masked Ph. Our study confirmed
and sized such deletions in 2 patients which where also
part of De Melo's cohort. CML-T1 also had a 8.7 Mb dele-
tion of 9q34 material in one of the sub-clones, but in this
case the loss was found to affect the homologue not
involved in the BCR/ABL1 formation.
We identified a duplication of the chromosome 22 har-
boring the BCR/ABL1 fusion accompanied by loss of the
normal homologue in 1 out of 9 patients in this study
plus the cell line CML-T1. Such duplications of the BCR/
ABL1 bearing chromosome (either chromosome 22 or 9)
seem to be a relatively common event in Ph negative BCR/
ABL1 positive CML patients, being accompanied by loss
of the normal homologue in most of the cases and seen
both in chronic phase and blast crisis [33-35].
Regarding the formation of the fusion gene in Ph negative
BCR/ABL1  positive CML patients, Morris et al [6] sug-
gested two possible mechanisms: a one step model, where
BCR/ABL1  results from a simple insertion of either 3'
ABL1 into BCR or 5' BCR into ABL after three genomic
breaks; and a multiple step model, with an initial classical
t(9;22)(q34;q11) followed by a second translocation of
both products and/or a third chromosome, requiring a
minimum of 4 genomic breaks.
Our study provided evidence for the existence of both
mechanisms implicated in the formation of the fusion
gene in Ph negative patients. We found a simple insertion
(one step event) in 6 out of 9 patients (no 1–3, 8–10) and
CML-T1 (no 5), with no evidence of secondary rearrange-
ments within the regions flanking BCR and ABL1 break-
points apart from the accompanying deletions seen in 2
patients and CML-T1. On the other hand, traces of
sequential rearrangements indicating a multiple step
mechanism were found in 3 patients. Patient no 4 had a
9q34 insertion at chromosome 22 with bits from 22q11
distal to the breakpoint embedded within the der(9), sug-
gesting an initial t(9;22)(q34;q11) followed by further
translocation of both products. Patient no 7 carried the
BCR/ABL1 fusion at 22p11. Sequences downstream of the
breakpoint remained at their original location, while 5'
BCR and all 9q34 sequences distal to ABL1 breakpoint
(including the telomere) were relocated at 22p11, which
could be explained by an initial t(9;22)(q34;q11) fol-
lowed by a three-way translocation between 9q34, 22q11
and 22p11. This sequence of events would have required
5 breaks (2 for the translocation and 3 for the second
one). However, an initial ins(9;22) followed by a recipro-
cal translocation between 9q34 and 22p11 would also
require 5 breaks and therefore cannot be ruled out.
Finally, patient no 6 had a three way cryptic
t(9;22;16)(q34;q11;q?13) with 9q34 sequences embed-
ded within the der(22), suggesting an initial ins(22;9) fol-
lowed by a translocation between chromosomes 16 and
der(22)ins(22;9). These data show not only that the two
mechanisms do happen, but also that they are not exclud-
ing options. An example of the latter is patient no 6, where
an initial direct ins(22;9) would be part of the spectrum
of rearrangements that had restored the normal morphol-
ogy of the der(22).
Conclusion
In summary, we found that the BCR/ABL1 fusion resulted
from relocation of not only the 3' ABL1 sequences within
BCR at 22q11.2 or 5' BCR sequences within ABL but also
a considerable amount of flanking material, with distal
recurrent breakpoints of the excised 3' ABL1 sequences at
RAPGEF1 and RXRA regions. BCR/ABL1 resulted from a
direct insertion (one step mechanism) in 6 patients and
CML-T1, while in 3 patients the fusion gene was a result
of a sequence of events (multiple steps). Finally, the pres-
ence of different rearrangements of both 9q34 and 22q11
regions demonstrates the genetic heterogeneity of this
subgroup of CML. Future studies should be performed to
confirm the presence of true breakpoint hot spots and
assess their implications in Ph negative BCR/ABL1 posi-
tive CML.
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